Barry J. Gertz - Concepedia

Author

Barry J. Gertz

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

B J Gertz, BARRY J. GERTZ, Barry GERTZ, Barry Gertz, Barry J Gertz, Barry J. Gertz

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)KU Leuven United States Military Academy University of California, San Francisco Baylor College of Medicine

About

Barry J. Gertz is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	923
2	Health Sciences	5	5	315
3	Anesthesia	2	2	57
4	Social Sciences	1	1	52
5	Cell Biology	1	1	52

Barry J. Gertz

Publications

6.2K

Citations

H-Index

Page 1

	Year	Citations
Effects of Specific Inhibition of Cyclooxygenase-2 on Sodium Balance, Hemodynamics, and Vasoactive Eicosanoids Francesca Catella-Lawson, Brendan McAdam, Briggs Morrison, Journal of Pharmacology and Experimental Therapeutics	1999	595
Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization Terry P. Combs, John A. Wagner, Joel P. Berger, Endocrinology	2002	566
Regulation of muscle growth by multiple ligands signaling through activin type II receptors Se‐Jin Lee, Lori A. Reed, Monique V. Davies, Proceedings of the National Academy of Sciences	2005	493
Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist Rudolph M. Navari, Rick R. Reinhardt, Richard J. Gralla, New England Journal of Medicine	1999	370
Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX‐2 versus COX‐1 in Healthy Volunteers Anne Van Hecken, Jules I. Schwartz, Marleen Depré, The Journal of Clinical Pharmacology	2000	355
Effect of Cyclooxygenase-2 Inhibition on Renal Function in Elderly Persons Receiving a Low-Salt Diet Suzanne K. Swan, David W. Rudy, Kenneth C. Lasseter, Annals of Internal Medicine	2000	336
Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal Osteoporosis Sohail A. Khan, John А. Kanis, Samuel D Vasikaran, Journal of Bone and Mineral Research	1997	290
Studies of the oral bioavailability of alendronate* Barry J. Gertz, Sherry D. Holland, W. F. Kline, Clinical Pharmacology & Therapeutics Oral BioavailabilityGastric PhMetabolic Bone DiseaseMedicineClinical Nutrition	1995	258
Prevention of Cisplatin-Induced Emesis by the Oral Neurokinin-1 Antagonist, MK-869, in Combination With Granisetron and Dexamethasone or With Dexamethasone Alone José Rodrigues Pereira, Rick R. Reinhardt, Carlos Carracedo, Journal of Clinical Oncology	2001	221
Dose-Response Relationships for Alendronate Treatment in Osteoporotic Elderly Women<sup>1</sup> Henry G. Bone, Robert W. Downs, Joseph Tucci, The Journal of Clinical Endocrinology & Metabolism	1997	188

Page 1